Novel method to process cystic fibrosis sputum for determination of oxidative state

Respiration

Volumn 80, Issue 5, 2010, Pages 393-400

  Hector, A ^a   Jonas, F ^a   Kappler, M ^a   Feilcke, M ^a   Hartl, D ^a   Griese, M ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cystic fibrosis; Dithiothreitol; Glutathione; Induced sputum

Indexed keywords

CD11B ANTIGEN; CD63 ANTIGEN; DIHYDRORHODAMINE 123; DITHIOTHREITOL; GLUTATHIONE; LEUKOCYTE ELASTASE;

ADULT; ARTICLE; CELL COUNT; CELL VIABILITY; CLINICAL ARTICLE; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; LUNG FIBROSIS; MALE; NEUTROPHIL; PRIORITY JOURNAL; SPUTUM ANALYSIS;

ADULT; ANTIGENS, CD; ANTIGENS, CD11B; BIOLOGICAL MARKERS; CELL COUNT; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYSTIC FIBROSIS; DITHIOTHREITOL; FEMALE; FLOW CYTOMETRY; GLUTATHIONE; HUMANS; INDICATORS AND REAGENTS; LEUKOCYTE ELASTASE; MALE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, INTERLEUKIN-8A; RHODAMINES; SPUTUM;

EID: 77958025778     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000271607     Document Type: Article

References (46)

1. Dodge JA: Why screen for cystic fibrosis? A clinicia n's v iew. Acta Paediatr Suppl 1999; 88: 28-32.
2. Rommens JM, Iannuzzi MC, Kerem B, Drumm ML, Melmer G, Dean M, Rozmahel R, Cole JL, Kennedy D, Hidaka N: Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245: 1059-1065. (Pubitemid 19231813)
3. Suri R, Metcalfe C, Lees B, Grieve R, Flather M, Norma nd C, T hompson S, Bush A, Wa l lis C: Comparison of hypertonic saline and alternate-day or daily recombinant human de-oxyribonuclease in children with cystic fi-brosis: a randomised trial. Lancet 2001; 358: 1316-1321.
4. Sagel SD: Noninvasive biomarkers of airway inflammation in cystic fibrosis. Curr Opin Pu lm Med 2003; 9: 516-521.
5. Brown RK, Kelly FJ: Evidence for increased oxidative damage in patients with cystic fi-brosis. Pediatr Res 1994; 36:487-493.
6. Linsdell P, Hanrahan JW: Glutathione permeability of CFTR. Am J Physiol 1998; 275: C323-C326.
7. Roum JH, Buhl R, McElvaney NG, Borok Z, Crystal RG: Systemic deficiency of glutathi-one in c ystic fibrosis. J Appl Physiol 1993; 75: 2419-2424.
8. Griese M, Ramakers J, Krasselt A, Starosta V, Van Koningsbruggen S, Fischer R, Ratjen F, Mullinger B, Huber RM, Maier K, Rietschel E, Scheuch G,Improvement of alveolar glu-tathione and lung function but not oxidative state in cystic fibrosis, Am J Respir Crit Care Med, 2004, 169, 822-828
9. 9Haddad JJ, Safieh-Garabedian B, Saade NE, Land SC: Thiol regulation of pro-inflammatory cytokines reveals a novel immunophar-macological potential of glutathione in the alveolar epithelium. J Pharmacol Exp Ther 2001; 296: 996-1005.
10. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg LA: High-dose oral N-acetylcysteine, a glutathi-one prodrug, modulates inflammation in cystic fibrosis. Proc Natl Acad Sci USA 2006; 103: 4628-4633.
11. Hartl D, Starosta V, Maier K, Beck-Speier I, Rebhan C, Becker BF, Latzin P, Fischer R, Ratjen F, Huber RM, Rietschel E, Krauss-Etschmann S, Griese M: Inhaled glutathione decreases PGE2and increases lymphocytes in cystic fibrosis lungs. Free Radic Biol Med 2005; 39:463-472.
12. Haddad JJ: Glutathione depletion is associated with augmenting a proinflammatory signal: evidence for an antioxidant/pro-oxi-dant mechanism regulating cytokines in the alveolar epithelium. Cytokines Cell Mol Ther 2000; 6:177-187.
13. Rahman I, MacNee W: Oxidative stress and adaptive response of glutathione in bronchial epithelial cells. Clin Exp Allergy 2002; 32: 486-488. (Pubitemid 34429564)
14. Hudson VM: Rethinking cystic fibrosis pathology: the critical role of abnormal reduced glutathione (GSH) transport caused by CFTR mutation. Free Radic Biol Med 2001; 30: 1440-1461.
15. Efthimiadis A, Pizzichini MM, Pizzichini E, Dolovich J, Hargreave FE: Induced sputum cell and fluid-phase indices of inflammation: comparison of treatment with dithioth-reitol versus phosphate-buffered saline. Eur Respir J 1997; 10:1336-1340.
16. Bartoli ML, Di Franco A, Vagaggini B, Bacci E, Cianchetti S, Dente FL, Tonelli M, Pag-giaro PL: Biological markers in induced sputum of patients with different phenotypes of chronic airway obstruction. Respiration 2009; 77: 265-272.
17. Zeng M, Wen Y, Liu LY, Wang H, Guan KP, Huang X: Role of TNF-alpha, STNF-R55 and STNF-R75 in inflammation of acute exacerbations of chronic obstructive pulmonary disease. Respiration 2009; 78: 399-403.
18. Aitken ML, Greene KE, Tonelli MR, Burns JL, Emerson JC, Goss CH, Gibson RL: Analysis of sequential aliquots of hypertonic saline solution-induced sputum from clinically stable patients with cystic fibrosis. Chest 2003; 123:792-799.
19. Economidou F, Samara KD, Antoniou KM, Siafakas NM: Induced sputum in interstitial lung diseases: novel insights in the diagnosis, evaluation and research. Respiration 2009; 77: 351-358.
20. Mazur W, Stark H, Sovijarvi A, Myllarniemi M, Kinnula VL: Comparison of 8-isopros-tane and interleukin-8 in induced sputum and exhaled breath condensate from asymptomatic and symptomatic smokers. Respiration 2009; 78: 209-216.
21. Henig NR, Tonelli MR, Pier MV, Burns JL, Aitken ML: Sputum induction as a research tool for sampling the airways of subjects with cystic fibrosis. Thorax 2001; 56:306-311.
22. Damjanov N, Ostojic P, Kaloudi O, Alari S, Guiducci S, Stanflin N, Nestorovic B, Kne-zevic J, Camiciottoli G, Porta F, Pistolesi M, Ibba-Manneschi L, Conforti ML, Candelieri A, Matucci Cerinic M: Induced sputum in systemic sclerosis interstitial lung disease: comparison to healthy controls and bron-choalveolar lavage. Respiration 2009; 78: 56-62.
23. Louis R, Shute J, Goldring K, Perks B, Lau LC, Radermecker M, Djukanovic R: The effect of processing on inflammatory markers in induced sputum. Eur Respir J 1999; 13: 660-667.
24. Wang F, He B: The effect of dithiothreitol on chemotactic factors in induced sputum of chronic obstructive pulmonary disease patients. Respiration 2009; 78: 217-222.
25. Beier J, Beeh KM, Kornmann O, Buhl R: Induced sputum methodology: validity and reproducibility of total glutathione measurement in supernatant of healthy and asthmatic individuals. J Lab Clin Med 2004; 144: 38-44.
26. Erin EM, Jenkins GR, Kon OM, Zacharasie-wicz AS, Nicholson GC, Neighbour H, Ten-nant RC, Tan AJ, Leaker BR, Bush A, Jose PJ, Barnes PJ, Hansel TT: Optimized dialysis and protease inhibition of sputum dithioth-reitol supernatants. Am J Respir Crit Care Med 2008; 177:132-141.
27. Woolhouse IS, Bayley DL, Stockley RA: Effect of sputum processing with dithiothreitol on the detection of inflammatory mediators in chronic bronchitis and bronchiectasis. Thorax 2002; 57:667-671.
28. Kelly MM, Keatings V, Leigh R, Peterson C, Shute J, Venge P, Djukanovic R: Analysis of fluid-phase mediators. Eur Respir J 2002; 20(suppl 37):24s-39s.
29. Dauletbaev N, R ick ma nn J, Viel K, Diegel H, von Mallinckrodt C, Stein J, Wagner TO, Bargon J: Antioxidant properties of cystic fi-brosis sputum. Am J Physiol Lung Cell Mol Physiol 2005; 288:L903-L909.
30. Dauletbaev N, Rickmann J, Viel K, Buhl R, Wagner TO, Bargon J: Glutathione in induced sputum of healthy individuals and patients with asthma. Thorax 2001; 56:13-18.
31. Beeh KM, Beier J, Koppenhoefer N, Buhl R: Increased glutathione disulfide and nitroso-thiols in sputum supernatant of patients with stable COPD. Chest 2004; 126: 1116-1122.
32. Beier J, Beeh KM, Kornmann O, Buhl R: Stability of glutathione in induced sputum: impact of freezing. Respiration 2003; 70: 523-527.
33. Hilliard JB: Standard Operating Procedures on Sputum Processing- Therapeutics Development Network Coordinating Center (TDN-CC), 2003.
34. Kuhn KS, Krasselt AI, Furst P: Glutathione and glutathione metabolites in small tissue samples and mucosal biopsies. Clin Chem 2000; 46: 1003-1005.
35. Kamencic H, Lyon A, Paterson PG, Juurlink BH: Monochlorobimane fluorometric method to measure tissue glutathione. Anal Bio-chem 2000; 286:35-37.
36. Hilliard JB, Konstan MW, Davis PB: Inflammatory mediators in CF patients. Methods Mol Med 2002; 70: 409-431.
37. Bland JM, Altman DG: Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
38. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML, Ramsey BW, Rosen-stein BJ, Smith AL, Wohl ME: Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994; 331: 637-642.
39. Liu H, Lazarus SC, Caughey GH, Fahy JV: Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosino-phils in vitro. Am J Physiol 1999; 276:L28-L34.
40. Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ: Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160:1635-1639.
41. Holmes WE, Lee J, Kuang WJ, Rice GC, Wood WI: Structure and functional expression of a human interleukin-8 receptor. Science 1991; 253: 1278-1280 .
42. Griese M, Latzin P, Kappler M, Weckerle K, Heinzlmaier T, Bernhardt T, Hartl D: Al-pha1-antitrypsin inhalation reduces airway inflammation in cystic fibrosis patients. Eur Respir J 2007; 29:240-250.
43. Kim JS, Hackley GH, Okamoto K, Rubin BK: Sputum processing for evaluation of inflammatory mediators. Pediatr Pulmonol 2001; 32:152-158.
44. Pineda-Molina E, Klatt P, Vazquez J, Marina A, Garcia de Lacoba M, Perez-Sala D, Lamas S: Glutathionylation of the P50 subunit of NF-kappaB: a mechanism for redox-induced inhibition of DNA binding. Biochemistry 2001; 40: 14134-14142.
45. Rahman I, Mulier B, Gilmour PS, Watchorn T, Donaldson K, Jeffery PK, MacNee W: Ox-idant-mediated lung epithelial cell tolerance: the role of intracellular glutathione and nuclear factor-kappaB. Biochem Pharmacol 2001; 62: 787-794.
46. Kraemer PS, Sanchez CA, Goodman GE, Jett J, Rabinovitch PS, Reid BJ: Flow cytometric enrichment for respiratory epithelial cells in sputu m. Cy tometry A 2004; 60: 1-7.